Conference Reports

Singapore
17 November 2017 - 19 November 2017
San Diego, California, US
24 September 2017 - 27 September 2017
Madrid, Spain
08 September 2017 - 12 September 2017
Madrid
22 June 2017 - 25 June 2017
Chicago, Illinois, US
02 June 2017 - 06 June 2017
Geneva
05 May 2017 - 08 May 2017
Orlando, Florida
16 February 2017 - 18 February 2017
Amsterdam
27 January 2017 - 30 January 2017
Singapore
16 December 2016 - 19 December 2016
San Diego, California
03 December 2016 - 06 December 2016
San Antonio, Texas
06 December 2016 - 10 December 2016
Vienna
04 December 2016 - 07 December 2016
Copenhagen
07 October 2016 - 11 October 2016
Singapore
20 July 2016 - 24 July 2016
Chiang Mai
13 May 2016 - 15 May 2016
Geneva
13 April 2016 - 16 April 2016
San Francisco, CA
07 January 2016 - 09 January 2016
San Antonio, Texas, US
08 December 2015 - 12 December 2015
Orlando, Florida, US
05 December 2015 - 08 December 2015
San Antonio, TX
18 October 2015 - 21 October 2015
Vienna
25 September 2015 - 29 September 2015
Philadelphia, PA
18 April 2015 - 22 April 2015
Geneva
15 April 2015 - 18 April 2015
San Antonio, TX
09 December 2014 - 13 December 2014
San Francisco, CA
06 December 2014 - 09 December 2014
21 November 2014 - 22 November 2014
Chicago, Illinois
30 May 2014 - 03 June 2014
Tel Aviv
18 June 2014 - 19 June 2014
Geneva
26 March 2014 - 29 March 2014
San Antonio
10 December 2013 - 14 December 2013
New Orleans, Louisiana
07 December 2013 - 10 December 2013
Amsterdam
27 September 2013 - 01 October 2013
Chicago, Illinois
31 May 2013 - 04 June 2013
Washington D.C
06 April 2013 - 10 April 2013
08 November 2012 - 09 November 2012
San Antonio Texas
04 December 2012 - 08 December 2012
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.